RudaCure Inc. was selected for the 中小企业部' 2021 Big3 Commercialization Support Project, which will support the commercialization not only of the currently ongoing RCI001, but also of 疼痛治疗药 RCI002, 特应性皮炎 treatment RCI003, anti-metastatic cancer treatment RCI004, and age-related 黄斑变性 treatment RCI005.
Along with the previously selected 科学技术信息通信部 Bio iCORE project, the company received high scores from evaluators across various fields for its 国内外 commercialization activities.
In particular, for this Big3 Commercialization Project, the company was recognized for its ability to secure core technology development through excellent technical personnel and research facilities, as well as the management team's capability in technology development and clinical advancement. As a result, the company will receive KRW 150 million in funding through the end of this year.
The company plans to devote all efforts to increasing the value of the drugs currently under development by accelerating 国内外 business activities through various government support programs.